Volume 67, Issue 6, Pages (June 2015)

Slides:

Advertisements

Similar presentations

Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: Data from >600 patients in the control arm of the STAMPEDE trial (MRC.

Advertisements

Docetaxel +/- zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE & treatment effects within subgroups (NCT )

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive,

Volume 50, Issue 1, Pages (July 2006)

Volume 51, Issue 2, Pages (February 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 378, Issue 9809, Pages (December 2011)

Volume 56, Issue 6, Pages (December 2009)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 61, Issue 6, Pages (June 2012)

Volume 68, Issue 4, Pages (October 2015)

Association between Smoking, Passive Smoking, and Erectile Dysfunction: Results from the Boston Area Community Health (BACH) Survey Varant Kupelian,

Volume 17, Issue 2, Pages (February 2016)

Volume 53, Issue 5, Pages (May 2008)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 52, Issue 2, Pages (August 2007)

Volume 70, Issue 2, Pages (August 2016)

Prostate Cancer Epidemic in Sight?

Volume 72, Issue 5, Pages (November 2017)

Volume 68, Issue 4, Pages (October 2015)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

Volume 74, Issue 1, Pages (July 2018)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 67, Issue 3, Pages (March 2015)

Volume 387, Issue 10024, Pages (March 2016)

Volume 66, Issue 3, Pages (September 2014)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 70, Issue 5, Pages (November 2016)

Volume 69, Issue 6, Pages (June 2016)

Volume 71, Issue 5, Pages (May 2017)

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

Volume 74, Issue 3, Pages (September 2018)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 6, Pages (June 2008)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 66, Issue 2, Pages (August 2014)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

The Economic Costs of Overactive Bladder in Germany

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial

Volume 62, Issue 6, Pages (December 2012)

Volume 70, Issue 2, Pages (August 2016)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 15, Issue 4, Pages (April 2014)

Volume 73, Issue 5, Pages (May 2018)

Volume 55, Issue 6, Pages (June 2009)

Volume 71, Issue 5, Pages (May 2017)

Volume 66, Issue 5, Pages (November 2014)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 72, Issue 2, Pages (August 2017)

Volume 10, Issue 9, Pages (September 2009)

Volume 74, Issue 6, Pages (December 2018)

Volume 392, Issue 10162, Pages (December 2018)

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Volume 378, Issue 9809, Pages (December 2011)

Volume 17, Issue 2, Pages (February 2016)

European Urology Oncology

Volume 13, Issue 5, Pages (May 2012)

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis Sarah Burdett, Liselotte M. Boevé,

Volume 51, Issue 2, Pages (February 2007)

Volume 67, Issue 4, Pages (April 2015)

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Volume 392, Issue 10162, Pages (December 2018)

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer Alex P. Hoyle, Adnan Ali, Nicholas D. James, Adrian Cook, Christopher.

Presentation transcript:

Volume 67, Issue 6, Pages 1028-1038 (June 2015) Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019) Nicholas David James, Melissa R. Spears, Noel W. Clarke, David P. Dearnaley, Johann S. De Bono, Joanna Gale, John Hetherington, Peter J. Hoskin, Robert J. Jones, Robert Laing, Jason F. Lester, Duncan McLaren, Christopher C. Parker, Mahesh K.B. Parmar, Alastair W.S. Ritchie, J. Martin Russell, Räto T. Strebel, George N. Thalmann, Malcolm D. Mason, Matthew R. Sydes European Urology Volume 67, Issue 6, Pages 1028-1038 (June 2015) DOI: 10.1016/j.eururo.2014.09.032 Copyright © 2014 The Authors Terms and Conditions

Fig. 1 Patient selection process for this newly diagnosed M1 control-arm cohort analysis. European Urology 2015 67, 1028-1038DOI: (10.1016/j.eururo.2014.09.032) Copyright © 2014 The Authors Terms and Conditions

Fig. 2 Failure-free and overall survival for newly diagnosed M1 patients in the STAMPEDE trial control arm. FFS=failure-free survival; IQR=interquartile range. European Urology 2015 67, 1028-1038DOI: (10.1016/j.eururo.2014.09.032) Copyright © 2014 The Authors Terms and Conditions

Fig. 3 Failure-free survival by metastatic site, Gleason-sum score category, World Health Organisation performance status, and age at randomisation. WHO PS=World Health Organization performance status. European Urology 2015 67, 1028-1038DOI: (10.1016/j.eururo.2014.09.032) Copyright © 2014 The Authors Terms and Conditions

Fig. 4 Overall survival by metastatic site, Gleason-sum score category, World Health Organization performance status, and age at randomisation. WHO PS=World Health Organization performance status. European Urology 2015 67, 1028-1038DOI: (10.1016/j.eururo.2014.09.032) Copyright © 2014 The Authors Terms and Conditions